(Total Views: 536)
Posted On: 08/21/2025 9:22:45 AM
Post# of 156316
There we have it. 1 of the Ladies of Leronlimab is in fact a brain mets survivor. Said odds are we might have a brain survivor. I forget who replied with past data it was unlikely. Would be nice, but unlikely.
From MGK's transcripting & thanks!! :
[00:20:08]: About a third of them had brain metastasis, two-thirds of them had organ metastasis. Their survival based on historical data should have been measured in weeks and months.
[00:20:55]: We found patients, actually eight [8] of the 42 patients from across the cancer studies who are still alive today and in particular five patients who had metastatic triple negative breast cancer of which three we have recently now confirmed have no evidence of disease including two patients that had lung mets and one patient that had lung and brain mets.
00:28:27] We're seeing evidence of sustained remission, which is you know, just unheard of in a patient with lung and and brain mets.
[00:32:25]: [00:32:25]: So the idea is with patients with recurrent glioblastoma who have absolutely no treatment options, we want to give them Leronlimab in advance of their surgery, measure their PD-L1 induction and then offer them a checkpoint inhibitor with the hopes that the checkpoint activity is in the periphery, [because the ICI doesn't cross the BBB, but can reach the periphery], and then activated cells can then enter the brain and attack the [GBM] cancer that has had a disrupted micro-environment. It's a bit of a bank-shot. But one tries what one can.
____
If Leronlimab succeeds in creating that route into the brain for an ICI, there is no need for companies on-going AAV-Vector delivery of ICI's.
Speechless to the implications for LL/ICI combo.
From MGK's transcripting & thanks!! :
[00:20:08]: About a third of them had brain metastasis, two-thirds of them had organ metastasis. Their survival based on historical data should have been measured in weeks and months.
[00:20:55]: We found patients, actually eight [8] of the 42 patients from across the cancer studies who are still alive today and in particular five patients who had metastatic triple negative breast cancer of which three we have recently now confirmed have no evidence of disease including two patients that had lung mets and one patient that had lung and brain mets.
00:28:27] We're seeing evidence of sustained remission, which is you know, just unheard of in a patient with lung and and brain mets.
[00:32:25]: [00:32:25]: So the idea is with patients with recurrent glioblastoma who have absolutely no treatment options, we want to give them Leronlimab in advance of their surgery, measure their PD-L1 induction and then offer them a checkpoint inhibitor with the hopes that the checkpoint activity is in the periphery, [because the ICI doesn't cross the BBB, but can reach the periphery], and then activated cells can then enter the brain and attack the [GBM] cancer that has had a disrupted micro-environment. It's a bit of a bank-shot. But one tries what one can.
____
If Leronlimab succeeds in creating that route into the brain for an ICI, there is no need for companies on-going AAV-Vector delivery of ICI's.
Speechless to the implications for LL/ICI combo.
(10)
(0)
